Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Cancerología
Print version ISSN 0123-9015
Abstract
MONTOYA-RESTREPO, María Elvira; GOMEZ-WOLFF, Luis Rodolfo; SANCHEZ-JIMENEZ, Astrid Viviana and GARCIA-GARCIA, Héctor Iván. Characteristics and survival of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. rev.colomb.cancerol. [online]. 2018, vol.22, n.3, pp.112-118. ISSN 0123-9015. https://doi.org/10.1016/j.rccan.2018.09.002.
Introduction:
There are multiple risk factors associated with the prognosis of survival of metastatic breast cancer (MBC). The two major risk factors are the expression of hormonal receptors (HR) and HER 2 neu, and the reason why they are requested in every MBC patient. The large majority (80%) of breast tumors are HR positive, and 20% are HER 2 positive. The aim of this study was to determine the prognostic factors associated with the overall survival (OS) of patients diagnosed with HER 2 positive MBC seen between January 2009 and December 2015 in the Instituto de Cancerología (Medellín-Colombia).
Methods:
A retrospective observational study was conducted, with survival analysis using the Kaplan-Meier method. The survival curves were compared using the Log-Rank Test, and factors associated with survival were analyzed using the Cox regression.
Results:
101 patients were included in the study. The median survival time was 46.6 months (Range 13-155 months), the 5-year OS was 41% (95% CI; 31%-50%) and the 10-year OS 13% (95% CI; 4%-30%). Higher overall survival was found for patients with relapsed disease, those with stages I and II, patients older than 40 years, postmenopausal, tumors with low histological grade and with co-expression of hormonal receptors. The patients with relapse of disease had a higher OS than the de novo patients after being adjusted for the other factors (HR: 0.47, 95% CI; 0.27-0.1).
Discussion:
The overall survival time is similar to that of other countries, as well as the lines of treatment and therapy received.
Keywords : Breast cancer; Receptor ErbB-2; Neoplasm Metastasis; Survival.